Onkologie. 2007:1(1):14-17
Treatment options in multiple myeloma
- Klinika hematológie a onkohematológie LF UPJŠ a FN L. Pasteura, Košice
Multiple myeloma is characterized by a high degree of resistance to conventional therapy, which results in a low complete remission rate and in limited survival.
The fact that high-dose therapy (HDT) can overcome tumor resistance resulting in a complete remission rate ranging from 25 to 50 %, has prompted the use of HDT followed by autologous stem cell rescue as part of the front-line therapy during the last 15 years.
The important issue concerning autologous transplantation is how to improve its efficacy. One way would be a tandem approach (double autologous or autologous followed by dose- reduced intensity allogeneis), the other way would consist of the incorporation of novel agents with new mechanisms of action such as thalidomide, lenalidomide and bortezomib.
Keywords: Key words: myeloma multiplex, autologous transplantation, thalidomide, lenalidomide, bortezomib. Key words MeSH: multiple myeloma – diagnosis, drug therapy; transplantation, autologous; thalidomide.
Published: May 5, 2007 Show citation
References
- Adam Z, Gregora E, Hájek R. Diagnostika a léčba mnohopočetného myelómu. Hematológie a transfuze dnes, 2003 (Suppl 1), s. 3-33.
- Kyle RA, Rajkumar SU. Multiple myeloma. N. Engl J Med 351, 2004, 1860-1873.
Go to original source... 
Go to PubMed... - Durie BGM. Multiple myeloma: Concise review of the disease and treatment options. International myeloma foudation, North Hollywood, 2004, p. 17-64.
- Hájek R, Ščudla V, Schutzová M, et al. Results of the CMG using autologous transplantation or autologous retransplantation. Haematologica, 2005, 90 (Suppl 1), p. 143-146.
- Dimopoulos M, Berenson J, Shirina N, Chen YM. Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels. Journal of Clinical Oncology, 24, 2006, p. 7505-7506. Go to original source...
- Yakoub - Agha I, Attal M, Dumonter CH, et al. Thalidomide in patients with advanced multiple myeloma: A study of 83 patients - report of the intergroupe francophone du myelome (IFM). The Hematology Journal 3, 2002, p. 185-192. Go to original source... Go to PubMed...
- Ghoblial IM, Rajkumar SU.: Management of Thalidomide toxicity. The Journal of Supportive Oncology, 1, 2003, 3, p. 1-12. Go to PubMed...
- Bruno B, Giaccone L, Rotta M, Anderson E. Novel targeted drugs for the treatment of multiple myeloma: From bench to bedside. Br. J.Haematol., 129, 2006, p. 755-762.
- Adams J. The proteasome: A suitable antineoplastic target. Nature, 4, 2004, p. 349-360. Go to original source... Go to PubMed...
- Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 2002, 9, p. 3063-3067. Go to original source... Go to PubMed...
- Barlett J, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivates as anticancer agents. Nature, 4, 2004, p. 1-9. Go to original source... Go to PubMed...
- Tóthová E, Kafková A. Bortezomib (Velcade): Prvý inhibítor proteazómu v liečbe chorých s mnohopočetným myelómom. Slovenský lekár, 16 (30), 2006, č. 5-6, s. 160-161.
- Ludwig H, Drach JM, Tóthová E, et al. Thalidomide -Dexamethasone vs Melphalane - Prednisone as first line treatment in elderly patients with multiple myeloma. Haematologica, 90, 2005 (Supplement 3), s. 399.
- Richardson P, Sonneveld P, Schuste, M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: Updates results of the APEX trial. NEJM, 352, 2005, s. 2487.